Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

DMRA stock hub

Damora Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

DMRAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.5B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

DMRA

In the news

Latest news · DMRA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-163.8

P25 -105.6P50 -46.5P75 -3.1

ROIC-17.8

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All DMRA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

171

Groups with data

Currency

USD

Showing 171 of 171 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001800315
Company name	Damora Therapeutics, Inc.
Country	United States
Country code	US
Employees	7
Employees Change	2%
Employees Change Percent	40
Enterprise value	$1.2B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-10-29
Isin	US36322Q2066
Last refreshed	2026-05-10
Market cap	$1.5B
Market cap category	Small-Cap
Price	$24.16
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	DMRA
Website	https://www.damoratx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-14.4%
FCF yield	-0.46%
P/B ratio	6.06x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-209.8M
Net Income Growth Years	0%
Profit Per Employee	$-30M
ROA	-16.46
Roa5y	-31.38
ROCE	-15.2
ROE	-163.8
Roe5y	-87.97
ROIC	-17.83

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	795.83%
Cagr3y	-23.33%
Cagr5y	-29.09%
EPS Growth Quarters	12
EPS Growth Years	3
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$260.5M
Cash	$257.6M
Current Assets	$260.4M
Current Liabilities	$20.1M
Debt	$68,000
Debt Equity	$0
Equity	$240.4M
Liabilities	$20.1M
Long Term Assets	$104,000
Long Term Liabilities	$81,000
Net Cash	$257.6M
Net Cash By Market Cap	$17.68
Net Cash Growth	1,726.38%
Net Debt Equity	$-1.07
Tangible Book Value	$-175.9M
Tangible Book Value Per Share	$-110
WACC	12.55

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	12.98
Net Working Capital	$-17.3M
Quick ratio	12.88
Working Capital	$240.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-17.79%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	794.48%
200-day SMA	17.65
3Y total return	-54.94%
50-day SMA	25.56
50-day SMA vs 200-day SMA	50over200
5Y total return	-82.07%
All Time High	449.8
All Time High Change	-94.63%
All Time High Date	2020-11-23
All Time Low	2.01
All Time Low Change	1,101.99%
All Time Low Date	2025-04-09
ATR	2.11
Beta	1.51
Beta1y	-4.23
Beta2y	0.1
Ch YTD	5
High	25.3
High52	38.33
High52 Date	2025-12-26
High52ch	-36.96%
Low	23.96
Low52	2.45
Low52 Date	2025-09-09
Low52ch	886.12%
Ma50ch	-5.48%
Price vs 200-day SMA	36.9%
RSI	43.87
RSI Monthly	50.79
RSI Weekly	52.34
Sharpe ratio	1.37x
Sortino ratio	7.97
Total Return	-17.79%
Tr YTD	5
Tr1m	-0.98%
Tr1w	-4.73%
Tr3m	-4.35%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Ratings	Buy
Earnings EPS Estimate	$-0.56
Operating Income	$-36.6M
Price target	$43
Price Target Change	$77.98

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	43,750,307%
Float Percent	72.55%
Shares Insiders	0.24%
Shares Institutions	2.06%
Shares Out	60,303,212
Shares Qo Q	11.55%
Shares Yo Y	17.79%
Short Float	2.55%
Short Ratio	3.78
Short Shares	1.85

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-7.8M
Average Volume	303,916.75x
Bv Per Share	-110.1
Ch1m	-0.98
Ch1w	-4.73
Ch1y	794.5
Ch3m	-4.35
Ch3y	-54.94
Ch5y	-82.07
Ch6m	388.1
Change	-3.32%
Change From Open	-3.4
Close	24.99
Days Gap	0.08
Depreciation Amortization	22,000
Dollar Volume	4,138,728.8
Earnings Date	2026-05-22
Earnings Time	amc
EBIT	$-36.6M
EBITDA	$-36.5M
EPS	$-154
F Score	1
FCF	$-6.7M
FCF EV Yield	-0.56x
FCF Per Share	$-0.11
Financing CF	266,844,000
Fiscal Year End	December
Founded	2,011
Income Tax	$50,000
Investing CF	-17,374,000
Iprfo	-93.56
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-19
Last Report Date	2025-12-31
Last Split Date	2024-08-30
Last Split Type	Reverse
Last10k Filing Date	2026-03-19
Ma150	22.41
Ma150ch	7.79%
Ma20	25.6
Ma20ch	-5.63%
Net CF	243,449,000
Next Earnings Date	2026-05-22
Open	25.01
Optionable	No
Position In Range	14.93
Ppne	104,000
Price Date	2026-05-08
Relative Volume	0.56x
Share Based Comp	1,037,000
Tr6m	388.08%
Us State	Massachusetts
Volume	171,305

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does DMRA pay a dividend?

Capital-return profile for this ticker.

Performance

DMRA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns DMRA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+2.1%

Float: +72.6% of shares outstanding

Insider ownership

+0.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

DMRA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

43.9

Neutral momentum band

Price vs 200-day MA

+36.9%

50/200-day relationship not available

Beta (5Y)

1.51

More volatile than the market

Sharpe ratio

1.37

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About DMRA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current DMRA stock rating?

Damora Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full DMRA analysis?

The full report lives at /stocks/DMRA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for DMRA?

The latest report frames DMRA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the DMRA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.